PRESS RELEASES

LATEST NEWS & PRESS RELEASES

2017

AXIM Biotech Files Patent on Controlled Release Chewing Gum to Provide Opioid Addiction Treatment

New York, June 23, 2017 – AXIM today announced that the company filed with the United States Patent and Trademark Office (USPTO) for U.S. Application Serial Number 62/410,469, a patent of invention that involves a chewing gum composition with controlled release of cannabinoids and opioid agonists and/or antagonists for addiction and/or dependence treatment.  Download PDF

AXIM Biotechnologies Secures Funding to Advance Clinical Trials and Bioequivalency Study

New York, June 19, 2017 – AXIM today announced that the Company has secured $4 million of institutional funding to further advance its clinical trials for the treatment of Irritable Bowel Syndrome (IBS), pain and spasticity in Multiple Sclerosis (MS), and to continue a bio-equivalency study on creating an alternative to Marinol® using the company’s patented chewing-gum delivery system. Download PDF

AXIM Biotech to Present at 2017 Marcum Microcap Conference in New York City

New York, June 14, 2017 – AXIM today announced that George Anastassov, MD, DDS, MBA and Chief Executive Officer of AXIM, will present at the 2017 Marcum Microcap Conference on June 15 at 9:00 am ET in the Uris Boardroom at the Grand Hyatt Hotel in New York City. Download PDF

AXIM Biotech to Present at 6th Annual SeeThruEquity Microcap Investor Conference in New York City

New York, June 1, 2017 – AXIM today announced that George Anastassov, MD, DDS, MBA and Chief Executive Officer of AXIM, will present at the SeeThruEquity Microcap Investor Conference in New York City on June 1, 2017 at 11:30am ET. Management will also be holding 1×1 meetings with investors at the Conference. Download PDF

AXIM Biotech to Present Research Abstracts at the 6th Pharmaceutical Sciences World Congress

New York, May 23, 2017 – AXIM today announced that Lekhram Changoer, Chief Technology Officer will present the company’s research at the upcoming 6th Pharmaceutical Sciences World Congress (PSWC), to be held from May 21-24, 2017 in Stockholm, Sweden. Download PDF

SeeThruEquity initiates coverage on AXIM® Biotech with a target price of $17.0

New York, May 16, 2017 – AXIM today announced that SeeThruEquity, a leading independent equity research firm focused on smallcap and microcap public companies has initiated coverage of AXIM with a price target of $17.0. Download PDF

AXIM® Biotech clinical study to develop Bioequivalent product to Marinol available on clinicaltrials.gov

New York, May 15, 2017 – AXIM today announced that information on the company’s Bioavailability Study on Dronabinol in a controlled-release, functional chewing gum form is now available on National Institutes of Health website Download PDF

AXIM® Biotech expands advisory board with Oncology specialist and medical Cannabis leading expert – Dr. Donald Abrams

New York, May 09, 2017 – AXIM® Biotechnologies today announced the addition to its advisory board of Dr. Donald Abrams, chief of the Hematology-Oncology Division at San Francisco General Hospital and a Professor of Clinical Medicine at the University of California San Francisco. Download PDF

AXIM® Biotech receives schedule 1 permit to move forward with development of MedChew RX® pharmaceutical chewing gum

New York, May 02, 2017 – AXIM today announced that the company’s product development partner Quay Pharmaceuticals Ltd. (“Quay Pharma”) has obtained the relevant licenses from the British Home Office to import and work with the controlled drugs that are required to continue the development of AXIM’s MedChew Rx® pharmaceutical chewing gum’s family of products. Download PDF

AXIM® Biotech to present at ExcipientFest 2017 in Providence, Rhode Island

New York, April 26, 2017 – AXIM today announced that Lekhram Changoer, Chief Technology Officer of AXIM Biotech, will deliver keynote presentation at the upcoming ExcipientFest 2017, to be held from April 25-26, 2017 at The Rhode Island Convention Center in Providence, RI. Download PDF

AXIM® Biotech advisory board member presented at CannMed 2017 personalized Cannabinoid Medicine Conference at Harvard

New York, April 13, 2017 – AXIM today announced that Dr. Ilya Reznik, a Board-certified specialist in Adult Forensic & Clinical Neuro Psychiatry and a member of the AXIM advisory board, presented at the CannMed 2017 Conference held at the Joseph B. Martin Conference at Harvard Medical School in Boston on April 9-11, 2017. Dr. Reznik presented a poster entitled “Cannabinoid-based Medicine as a Pivotal Model for Personalized Integrative Care” which was met with considerable interest by the scientific community. Download PDF

AXIM® Biotech to attend Biocentury’s 24th annual future leaders in the biotech industry conference in New York

New York, April 05, 2017 – AXIM today announced that George E. Anastassov, MD, DDS, MBA and Chief Executive Officer of AXIM Biotech, is scheduled to meet with business prospects and investors at BioCentury’s annual Future Leaders in the Biotech Industry Conference on April 7, 2017 at the Millennium Broadway Hotel & Conference Center in New York City. Download PDF

AXIM® Biotech enters term sheet agreement with US API company to develop Bioequvalent product to Marinol

New York, March 28, 2017 – AXIM today announced that it has entered into a Term Sheet Agreement with a U.S.-based controlled-substances API production company to develop a dronabinol-based functional, controlled-release chewing gum product based on AXIM IP and technology. The new dronabinol chewing gum product will be bioequivalent to Marinol®, and used to help treat patients with chemotherapy induced nausea and vomiting and AIDS patients experiencing appetite and weight loss. Since its market introductions, Marinol® remains the only FDA approved cannabis-based drug available in the US. Download PDF

AXIM® Biotech retains ora to manage upcoming product development and clinical trials on Glaucoma and dry eye indications

New York, March 21, 2017 – AXIM today announced that it has retained the services of Ora®, Inc., a global Contract Research Organization (“CRO”), to perform the company’s upcoming product development (based on AXIM’s IP) and clinical trials for treating glaucoma and dry eye utilizing cannabinoid-based therapeutics. Ora is the world’s leading ophthalmology CRO for advancing products from pre-clinical through approval and post-market phases. Download PDF

AXIM® Biotech announces enrolled patients begin phase II trial for the treatment of Irritable Bowel Syndrome with CanChew Plus® chewing gum

New York, March 07, 2017 – AXIM today announced enrollment of 40 patients and commencement of its Phase II clinical trial for the treatment of irritable bowel syndrome with the company’s CanChew Plus® CBD gum. The study is being conducted by Renger Witkamp, Professor and Chair in Nutrition and Pharmacology, at Wageningen University in the Netherlands. Download PDF

AXIM® Biotech announces the production of CanChew Plus®, the next generation controlled release CBD chewing gum

New York, March 01, 2017 – AXIM began production of CanChew Plus®, the next generation of the company’s award-winning controlled-release cannabidiol functional chewing gum. Download PDF

AXIM® Biotech to attend the 19th Annual Bio CEO & Investor Conference in New York

New York, Feb 09, 2017 – AXIM today announced that George E. Anastassov, MD, DDS, MBA and Chief Executive Officer of AXIM Biotech, is scheduled to meet with business prospects and investors at the annual BIO CEO & Investor Conference in New York from February 13-14, 2017 at the Waldorf Astoria Hotel in New York City. Download PDF

AXIM® Biotech holds annual board meeting

New York, Jan 25, 2017 – AXIM held its second annual board meeting on January 20, 2017 in New York City. AXIM Biotech board members reviewed company milestones in 2016, and discussed clinical trial progress for irritable bowel syndrome, multiple sclerosis and psoriasis and eczema as well as additional R&D activities for the next 12 months. The meeting also approved budgets needed to carry out the clinical projects and business developments. Download PDF

AXIM® Biotech enters IBS clinical trial for CanChew CBD chewing gum

New York, Jan 18, 2017 – AXIM entered clinical trial on treating irritable bowel syndrome with the company’s CanChew Plus® CBD gum at Wageningen University in the Netherlands. Download PDF

AXIM® Biotech attends Biotech showcase and J.P. Morgan Healthcare conferences in San Francisco

New York, Jan 10, 2017 – AXIM today announced that George E. Anastassov, MD, DDS, MBA and Chief Executive Officer of AXIM Biotech, is meeting with business prospects and investors at the Biotech Showcase 9th Annual Conference and the J.P. Morgan 35th Annual Healthcare Conference in San Francisco. Download PDF

AXIM® Biotech receives positive PK data results for CanChew Plus® CBD gum

New York, Jan 04, 2017 – AXIM received positive pharmacokinetic data results on its CanChew Plus® CBD Gum, and gears up for clinical trial on alleviating the symptom of irritable bowel syndrome. Download PDF

2016

AXIM® Biotech Expands Advisory Board to Broaden the Development of Cannabinoids’ Therapeutic Indications

MarketWatch, December 29, 2016 – Axim announced the addition of renowned Cardiac Anesthesiologist, Dr. Emil Engels MD, MBA, CPC. Dr. Emil Engel serves as Partner at Fairfax Anesthesiology Associates and American Anesthesiology of Virginia. See Full Article.

Axim® Biotech Announces Addition of World-Renowned Ophthalmologist to Advisory Board

GlobeNewswire,  December 27, 2016 – Axim added world-renowned surgeon and eye expert, Professor Robert Ritch to the Company’s Advisory Board. Prof. Ritch is the Surgeon Director Emeritus and Chief of Glaucoma Services at New York Eye and Ear Infirmary of Mount Sinai School of Medicine in New York (NYEE). See Full Article. . .

AXIM® Biotech Expands Advisory Board With Psychiatry Specialist, Dr. Ilya Reznik

MarketWatch, December 13, 2016 – Axim announced the addition to its Advisory Board of Dr. Ilya Reznik, a Board-certified specialist in Adult Forensic & Clinical Neuro Psychiatry at MaReNa Diagnostic and Consulting Center in Israel and a clinical practitioner utilizing medical cannabis inpatient treatment for over ten years. See Full Article

AXIM® Biotech Receives Medical Ethical Committee Approval to Begin IBS Trial for Canchew Plus® CBDGum

GlobeNewswire,  December 06, 2016 – AXIM announced today that it received approval from the Medical Ethical Committee (METC) of Wageningen University, The Netherlands, to begin a study on patients suffering from irritable bowel syndrome (IBS) with the Company’s CanChew Plus® CBD-containing chewing gum. Download PDF

AXIM® Biotech Selected by Fox Business as a “Top Five Biotech Stocks of 2016

Fox Business, November 29, 2016 – There have been better years for biotech stocks than 2016 has turned out to be. Concerns about a potential crackdown on excessive drug pricing cast a dark cloud over most drugmakers. However, despite headwinds for the broader industry, some biotech stocks performed very well. The “top five” list includes Axim Biotechnologies (NASDAQOTH: AXIM). Its stock has popped by more than 2,000% year to date, with most of those gains coming in the second half.  See Full Article

AXIM® Biotech Files IP Application on Proprietary Method to Extract High-Purity THC

GlobeNewswire,  November 29, 2016 – Axim announced today that it filed an IP application with the World Intellectual Property Organization (WIPO) on a proprietary method to extract THC-A (tetrahydrocannabinol acid) from cannabis plants and to achieve THC (tetrahydrocannabinol) with higher purity than conventional methods. Download PDF

Axim® Biotechnologies, Inc. Donates Flagship CanChew Gum to U.S. Pain Foundation to Help Chronic Pain Sufferers

GlobeNewswire, November 22, 2016 – Axim, a world leader in cannabinoid research and development, today announced that it donated 3,200 pieces of its hemp-derived CBD functional chewing gum CanChew® to the U.S. Pain Foundation to support the organization’s dedication in empowering caregivers and those who suffer from chronic pain. Download PDF

AXIM® Biotech Expands Patent Protection on Cannabinoid Chewing Gum — SECFilings.com

Marketwire, November 17, 2016 – SECFilings.com, a leading financial news and information portal offering free real-time public company filing alerts, announces an article on a new, extended patent for AXIM® Biotechologies’ (OTCQB:AXIM) cannabinoid-based chewing gum. See Full Article

New U.S. Patent Allowance Granted to AXIM® Biotech for Use of All Cannabinoids in Its Controlled-Release Chewing Gum Products

GlobeNewswire, November 16, 201 – Axim, a world leader in hemp cannabinoid research and development, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Application Serial Number 9,433,601, a patent that claims the use of all cannabinoids in cannabinoid-containing controlled-release chewing gum products. Download PDF

AXIM® Initiates New Studies & Pulls Ahead of the Competition — SECFilings.com

Marketwire,  November 07, 2016 – SECFilings.com, a leading financial news and information portal offering free real-time public company filing alerts, announces an article taking a closer look at AXIM Biotechnologies’ (OTCQB:AXIM) cannabinoid-based clinical trials program. See Full Article

Axim Biotechnologies Inc (OTCMKTS:AXIM) Looks Well Supported To Capitalize On Further Upside Potential

Insider Financial November 4, 2016 – Axim Biotechnologies Inc is running up up on news of its development pipeline advancing in some key early stage studies, and the company is drawing plenty of speculative capital as a result. There’s a lot of capital flowing into the marijuana space right now, much of it erroneous in advance of the spate of near term legalization votes, and so we thought we’d take a look at the catalysts behind Axim’s run in an attempt to identify whether or not the gains are warranted. See Full Article

Biotech Bets on the Booming Global Cannabis Industry

MoneyShow.Com November 04, 2016 – Although the biotech sector will be one of the greatest beneficiaries of the legal cannabis movement, the sector has recently been under pressure and this weakness has created significant opportunities for investors says Michael Berger, Editor of MoneyShow.com who highlights a few of the companies focused on this opportunity. See Full Article

AXIM® Biotechnologies, Inc. Posts Product Pipeline Chart for Pharmaceutical Clinical Trials Program in Cannabinoid R&D

Nasdaq Globe Newswire, November 03, 2016 – NEW YORK, Nov. 03, 2016 (GLOBE NEWSWIRE) — AXIM® Biotechnologies, Inc. (AXIM® Biotech) (OTC:AXIM), a world leader in cannabinoid research and development, today announced that it has published a product pipeline chart on its website that highlights the timelines from pre-clinical to a new drug application for its numerous intellectual property-protected cannabinoid-based products. Download PDF

AXIM Biotechnologies, Inc. CEO Speaks on Emerging Markets and Cannabis Drug Market at Money Show Dallas

Nasdaq Globe Newswire, October 19, 2016 – NEW YORK, Oct. 19, 2016 (GLOBE NEWSWIRE) — AXIM® Biotechnologies, Inc. (AXIM® Biotech) (AXIM), a world leader in cannabinoid research and development, announced that its Chief Executive Officer George E. Anastassov, MD, DDS, MBA, spoke at The Money Show Dallas about emerging cannabis markets and in particular the cannabis drug market. The Money Show Dallas took place Oct. 19-21 at the Hyatt Regency in Dallas. It is a conference for investors and traders in search of opportunities for diversification and profits across the globe. See full article

AXIM Biotechnologies, Inc. CEO to Speak at First-Ever National Symposium on Medical Cannabis for Healthcare Professionals in Mexico City

Nasdaq Globe Newswire, October 6. 2016 – NEW YORK, — AXIM® Biotechnologies, Inc. (AXIM® Biotech) (AXIM), a world leader in cannabinoid research and development announced that its Chief Executive Officer George E. Anastassov, MD, DDS, MBA, will speak at the first-ever symposium dedicated to providing the medical community of Mexico with information about the medical value of cannabidiol (CBD) derivatives in Mexico City on Oct. 8. See Full Article

AXIM® Biotech Signs Exclusive Distribution Agreement With Israel’s Rafa Pharmaceuticals

Nasdaq Globe Newswire, September 2016 – NEW YORK, Sept. 19, 2016 (GLOBE NEWSWIRE) — AXIM® Biotechnologies, Inc. (AXIM), an innovative biotechnology company focusing on research, development and production of pharmaceutical, nutraceutical and cosmetic products, announced that it signed an exclusive distribution agreement with Israel-based Rafa Laboratories, Ltd. for distribution of its award-winning cannabinoid chewing gum CanChew.®  See Full Article

AXIM® Biotech to Begin Human Clinical Trials on CBG for Psoriasis

FORBES, May 17, 2016 – An in-depth article that covers human dermatological clinical trials for Cannabinoid based solutions for psoriasis and eczema at the Maurits Clinic in The Hague, The Netherlands. See Full Article

Can Marijuana Save Your Skin—And Your Sex Life? Inside the New Topical Cannabis Phenomenon

Vogue.com, March 30, 2016 – The article mentions AximBioTech’s Oraximax, a forthcoming oral-care line that taps into the antibacterial and anti-inflammatory properties of the cannabinoid CBG. See Full Article

AXIM Biotechnologies, Inc. Increases CanChew Cannabidiol (CBD) Gum Donations By 200%

Nasdaq Globe Newswire, July 2016 – AXIM® Biotechnologies, Inc. (AXIM® Biotech), a world leader in hemp cannabinoid research and development, launched the Company’s community outreach and legacy customer reward program.  AXIM® Biotech selected Adopt-A-Soldier Platoon, Inc. as a charitable giving beneficiary that will distribute 3,600 units of award-winning CanChew®cannabidiol (CBD) controlled release chewing gum to U.S. Veterans.  AXIM® also expanded the Company’s appreciation program to include legacy customers.  In total, AXIM increased product donations by 200% year-over-year and is distributing all products in the month of July. See Full Article

AXIM® bags pot discount for gum to treat multiple sclerosis

Reuters, January 2016 – AXIM Biotechnologies Inc, a small, Manhattan-based company with ties to the Netherlands, says it has a trump card in its quest to develop a cannabis-based chewing gum to ease the symptoms of multiple sclerosis. The company says it will be able to price its gum cheaper than a major competitor after securing a “significant” discount on cannabis. See Full Article

AXIM® Biotech CEO Appointed to American Pain Association Board of Advisors, Addresses American Opioid Abuse Epidemic

 Nasdaq Globe Newswire, March 2016 – NEW YORK, March 31, 2016– Dr. George E. Anastassov, MD, DDS, MBA and Chief Executive Officer of AXIM ® Biotechnologies, Inc. was recently appointed to the American Pain Association’ s Board of Advisors. See Full Article

AXIM® Biotech Leads Cannabis Industry in Cannabinoid Research, Development and Intellectual Property; Tackles 15 Debilitating Conditions With No Known Cure

 Nasdaq Globe Newswire, February 2016 – NEW YORK, Feb. 18, 2016– Dr. George E. Anastassov, MD, DDS, MBA and Chief Executive Officer of AXIM ® Biotechnologies, Inc. shares the hemp innovator’ s vision and actions that position the Company as … See Full Article

STRATEGY
MANUFACTURING
FAQ
Close Menu

Mr. Huemoeller has over 35 years experience in investment banking, finance, sales and marketing. Mr. Huemoeller began his career as an investment advisor in 1982 with M.L. Stern & Company a municipal bond firm in California and became a registered principal in 1985. He has previously been registered with various state insurance boards, as well as with the Chicago Board of Trade as a commodities broker. Mr. Huemoeller has worked for Smith Barney, Drexel Burnham, Prudential Securities, and Paine Webber and has extensive experience in stocks, bonds, commodities, mergers and acquisitions, leveraged buyouts and private placement transactions.

        Mr. Huemoeller has served on the Board of Directors of AXIM Biotechnologies Inc., as Chairman of the Audit Committee, since July 2017.  Mr. Huemoeller also currently serves on the Board of Directors of Pledge Petroleum Corporation another publicly traded company (PROP).  Mr. Huemoeller also currently serves on the Executive Committee of Kettner Investments, LLC, a Delaware Limited Liability Company that is a holding Company.  Since April 2015, Mr. Huemoeller has been the Chief Executive Officer and President of Air Water Earth Inc., an environmental technology company.  From March 2013 to January 2016, Mr. Huemoeller was Chairman, Chief Executive Officer and Chief Financial Officer, of Propell Technologies Group Inc., an oilfield service and technology Company wherein he oversaw the investment of over $18,000,000 into the Company, publicly traded under the symbol PROP on the OTCBB markets. From April 2012 to March 2013, Mr. Huemoeller was the President of Joshua Tree Capital Inc., an independent corporate finance advisory firm specializing in providing strategic capital formation guidance to public and private small cap oil and gas companies. From March 2009 to April 2012, Mr. Huemoeller was a FINRA-registered investment banker focused on all aspects of taking company’s public, deal structure, capital markets and Institutional placement of both debt and equity transactions with Buckman, Buckman and Reid. From August 2008 to March 2009, Mr. Huemoeller worked with Greenstone Holdings Group, LLC; an advisory firm with an emphasis on helping Chinese companies go public in the United States from January 2008 to July 2008, Mr. Huemoeller worked at Aspenwood Capital, a division of Green Drake Securities as an Investment Banker. Mr. Huemoeller formerly served on the Board of Directors of NatureWell Inc., a publicly traded company engaged in migraine relief OTC sublingual products. Mr. Huemoeller previously served as Chairman and CEO of HumWare Media Corp, a publicly traded software development, media and technology company which he started in 1998 and was responsible for acquisition strategies and the day-to-day corporate operations. Mr. Huemoeller is co-author of U.S. Patent #5,855,005. Mr. Huemoeller completed various studies in the Bachelor of Business Administration Program at the University of Minnesota and has previously held Series 3, 7, 24, 63 and 79 Securities Licenses.

Lekhram Changoer is the Chief Technology Officer of AXIM Biotechnologies, Inc. as of May 2014. He holds a Bachelor’s Degree in Analytical/Organic Chemistry and a Master’s Degree in Organic Chemistry. He was one of the founders of CanChew Biotechnologies, LLC in 2012 and is board member and partner of Sanammad Foundation and Sanammad Pharmaceuticals BV; both companies originated and located in The Netherlands since 2009 and 2014, respectively. He is the originator of multiple patents including patent-pending technology on chewing gum compositions comprising cannabinoids, together with his Sanammad partners. He has over 20 years of experience in the area of Sales & Marketing, R&D, product development, and quality assurance of technical, consumer healthcare and pharmaceutical products – all servicing European and other international markets. During his career he has co-founded different intellectual property-based pharmaceutical and dental companies in different stages from clinical development to the global sales of registered products.


Dr. Philip. A. Van Damme is Chief Scientific/Medical Officer of AXIM Biotechnologies Inc., as of May 2014. Prior to that, Dr. Van Damme was one of the founders and CSO of CanChew Biotechnologies LLC, in 2012. He is also one of the founders and President/Director of Sanammad Foundation and Sanammad Pharmaceuticals, both originated and located in The Netherlands since 2009 and 2014, respectively. He is one of the developers of the first-in-the-world cannabinoid-containing chewing gum-based delivery systems. Dr. Van Damme possesses Dental and Medical Doctorates as well as a PhD in Medical Sciences, and has been actively involved in Research and Development in Dentistry, Medicine and Biotechnologies since 1983.

Dr. George E. Anastassov is the Founder of AXIM Biotechnologies, Inc. and Chairman of the Board. Prior to that Dr. Anastassov was one of the founders and the CEO of CanChew Biotechnologies, LLC in 2012. Dr. Anastassov is also one of the founders and a Board Member and a general partner of Sanammad Foundation and Sanammad Pharmaceuticals; both companies originated and located in The Netherlands since 2009 and 2014, respectively. He is one of the developers of the first-in-the-world cannabinoid-containing chewing gum-based delivery system.

Dr. Anastassov possesses Medical and Dental Doctorates as well as an Executive MBA. Dr. Anastassov has been recognized in “Who’s Who in Medicine” as well as “Who’s Who in Business Professionals” numerous times. He is the recipient of multiple national and international professional and humanitarian awards. Dr. Anastassov has been actively involved in Research and Development in Medicine and Biotechnologies since 1987.